Stockreport

Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

BIO-PATH HOLDINGS INC  (BPTH) 
Last bio-path holdings inc earnings: 11/14 04:20 pm Check Earnings Report
US:NASDAQ Investor Relations: biopathholdings.com
PDF Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Trea [Read more]